Mayne Pharma poised to enter world’s largest pharmaceutical market
Apr 16, 2020
Apr 16, 2020 |
2 min
Mayne Pharma Group Limited (ASX: MYX) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy.
Rat's Rant: What's hot, what's not and ... more biotech winners
Oct 3, 2019
Oct 3, 2019 |
7 min
Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.
